The fibroblast-synthesized chemokine CXCL12 contributes to this phase by enhancing malignant cell prospects for survival and via the aggressive recruitment of additional progenitor cells into the TME GF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells [48]. This evidence concerns the gene CD8A and neoplasm.